Articles

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Deo. of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto
Princess Margaret Cancer Centre, University Health Network, Toronto
Princess Margaret Cancer Centre, University Health Network, Toronto
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto,
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Vol. 106 No. 1 (2021): January, 2021 https://doi.org/10.3324/haematol.2019.235721